U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H22FN7O3
Molecular Weight 463.4652
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMG-337

SMILES

C[C@]([H])(c1nnc2c(cc(cn12)-c3cnn(C)c3)F)n4ccc5c(cc(cn5)OCCOC)c4=O

InChI

InChIKey=DWHXUGDWKAIASB-CQSZACIVSA-N
InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C23H22FN7O3
Molecular Weight 463.4652
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.amgenoncology-international.com/#/our-products/our-pipeline/

AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the cell surface enzyme called c-Met, which, when dysregulated, stimulates cancer cell scattering, invasion and protection from apoptosis. AMG 337, currently in Phase 2 development for the treatment of gastric and esophageal adenocarcinoma. In addition, recently was shown, that AMG 337 a promising and novel therapeutic strategy for targeting hepatocellular carcinomas with a dependence on HGF/MET signaling.

Approval Year

PubMed

PubMed

TitleDatePubMed
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology.
2015
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
2016 Jul
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
2016 Mar 24

Sample Use Guides

150 mg, 200 mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:53:10 UTC 2021
Edited
by admin
on Sat Jun 26 13:53:10 UTC 2021
Record UNII
08WG8S0L8D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMG-337
Common Name English
1,6-NAPHTHYRIDIN-5(6H)-ONE, 6-((1R)-1-(8-FLUORO-6-(1-METHYL-1H-PYRAZOL-4-YL)-1,2,4-TRIAZOLO(4,3-A)PYRIDIN-3-YL)ETHYL)-3-(2-METHOXYETHOXY)-
Systematic Name English
AMG 337 [WHO-DD]
Code English
Code System Code Type Description
ChEMBL
CHEMBL3545212
Created by admin on Sat Jun 26 13:53:10 UTC 2021 , Edited by admin on Sat Jun 26 13:53:10 UTC 2021
PRIMARY
CAS
1173699-31-4
Created by admin on Sat Jun 26 13:53:10 UTC 2021 , Edited by admin on Sat Jun 26 13:53:10 UTC 2021
PRIMARY
PUBCHEM
44181686
Created by admin on Sat Jun 26 13:53:10 UTC 2021 , Edited by admin on Sat Jun 26 13:53:10 UTC 2021
PRIMARY
DRUG BANK
DB15639
Created by admin on Sat Jun 26 13:53:10 UTC 2021 , Edited by admin on Sat Jun 26 13:53:10 UTC 2021
PRIMARY
FDA UNII
08WG8S0L8D
Created by admin on Sat Jun 26 13:53:10 UTC 2021 , Edited by admin on Sat Jun 26 13:53:10 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY